A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Tacrolimus (Primary) ; Tacrolimus
- Indications Allotransplant rejection
- Focus Pharmacokinetics
- Sponsors Astellas Pharma; Astellas Pharma Europe Ltd
Most Recent Events
- 18 Sep 2024 Planned End Date changed from 31 May 2026 to 31 Dec 2025.
- 04 Dec 2021 This trial has been completed in Poland, as per European Clinical Trials Database.
- 24 Feb 2021 Planned End Date changed from 1 May 2026 to 31 May 2026.